The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial

Chunhua Zhoua Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China;b The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, Shijiazhuang, People’s Republic of ChinaView further author information

Yuanzheng Qiuc CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaView further author information

Jianxin Wanga Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China;b The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, Shijiazhuang, People’s Republic of ChinaView further author information

Xiang Zhongc CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaView further author information

Xiufang Zhua Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ChinaView further author information

Xiaojing Huanga Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ChinaView further author information

Lan Yanga Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ChinaView further author information

Qiaolei Jic CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaView further author information

Feifei Zhouc CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaView further author information

Shunquan Wuc CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaView further author information

Mengjie Yangd NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of ChinaView further author information

Jing Zhangd NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of ChinaView further author information

Kaili Liuc CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaView further author information

Li Jic CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaView further author information

Hanyu Yangc CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaView further author information

Chunlei Lic CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, People’s Republic of ChinaCorrespondence[email protected]
View further author information

Yuanyuan Zhaoa Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ChinaCorrespondence[email protected]
View further author information

show all

The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial

Supplementary_materials_revised

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial

Supplementary_materials_revised

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date